EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
AA Aizer, N Lamba, MS Ahluwalia, K Aldape… - Neuro …, 2022 - academic.oup.com
Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …
known about brain metastases than cancer-related entities of similar incidence. Advances in …
[HTML][HTML] UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-LiNe setting (UNICORN)
Introduction Approximately 10% of EGFR mutations (EGFRmuts) are uncommon
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …
[HTML][HTML] Targeting EGFR in melanoma–the sea of possibilities to overcome drug resistance
J Pastwińska, K Karaś, I Karwaciak… - Biochimica et Biophysica …, 2022 - Elsevier
Melanoma is considered one of the most aggressive skin cancers. It spreads and
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …
[HTML][HTML] EGFR Mutations in Head and Neck Squamous Cell Carcinoma
S Nair, JA Bonner, M Bredel - International Journal of Molecular Sciences, 2022 - mdpi.com
EGFR is a prototypical receptor tyrosine kinase that is overexpressed in multiple cancers
including head and neck squamous cell carcinoma (HNSCC). The standard of care for …
including head and neck squamous cell carcinoma (HNSCC). The standard of care for …
[HTML][HTML] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
Introduction Real-world clinical outcomes in patients with advanced NSCLC harboring
EGFR exon 20 insertion (exon20ins) mutations have not been extensively studied. We …
EGFR exon 20 insertion (exon20ins) mutations have not been extensively studied. We …
[HTML][HTML] Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Besides platinum-based chemotherapy, no established treatment option exists for advanced
non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 (Ex20ins) insertion …
non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 (Ex20ins) insertion …
[HTML][HTML] Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
D Reita, L Pabst, E Pencreach, E Guérin, L Dano… - Cancers, 2021 - mdpi.com
Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …
[HTML][HTML] Understanding EGFR heterogeneity in lung cancer
The advances in understanding the inherited biological mechanisms of non-small cell lung
cancer harbouring epidermal growth factor receptor (EGFR) mutations led to a significant …
cancer harbouring epidermal growth factor receptor (EGFR) mutations led to a significant …